EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 256 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR High HPV Vaccination Coverage in England Associated with a Substantial Reduction in Cervical Cancer Mortality FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions MOST POPULAR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... February 11, 2026 Integrating Geriatric Assessment into Cancer Care: A Conversation with Dr. Supriya... September 11, 2018 Women and girls in science: We won’t stop pushing for progress February 11, 2023 Olaparib Maintenance Fails in Platinum Sensitive Advanced Non-Small Cell Lung Cancer March 26, 2021 Load more HOT NEWS Mom Thinks Baby Died Until Firefighters Say The Family Dog Made... Working Outdoors in the Sunshine May Lower Your Risk of Breast... Men’s skin cancer rates increase by 50% over decade Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom...
